Drug intelligence / Profile preview

MW02

Development stage: Phase 3
Lead developer: Jiangsu T-Mab Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

MW02 is a humanized monoclonal antibody that acts as an antagonist of vascular endothelial growth factor (VEGF). Its primary mechanism of action is the inhibition of VEGF activity, which plays a key role in angiogenesis. By blocking VEGF, MW02 aims to reduce abnormal blood vessel growth and leakage associated with diseases such as wet age-related macular degeneration. The drug was initially developed by Jiangsu T-Mab Biopharma and has reached Phase 3 clinical trials for wet age-related macular degeneration in China[1][3][4].

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on MW02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MW02.

Explore the full profile